SYNOPSIS Infusion of commercial preparations of porcine and bovine antihaemophilic globulin into three haemophilic patients produced transient thrombocytopenia. This platelet-aggregating activity has been shown to be present in a wide range of animal plasmas and is related to the fibrinogen fraction. The mechanism of platelet aggregation by animal fibrinogen is discussed and some inhibitors of the reaction are described.
Antihaemophilic globulin (AHG) prepared from bovine and porcine plasma is of proven value in the management of haemorrhage in haemophilia (Biggs, 1967) . It has been effectively used in human patients (Macfarlane, Biggs, and Bidwell, 1954; Macfarlane, Mallam, Witts, Bidwell, Biggs, Fraenkel, Honey, and Taylor, 1957; Macfarlane and Biggs, 1959; Biggs, 1960; Rizza and Biggs, 1969) , in haemophilic dogs (Sharp and Dike, 1963) , and in a haemophilic horse (Nossel, Archer, and Macfarlane, 1962) . Bovine AHG at concentrations of 05 mg/ml produces platelet aggregation both in vitro (Sharp and Bidwell, 1957) and invariably in vivo (Macfarlane and Biggs, 1959) . Thrombocytopenia was also recorded in the haemophilic horse treated with bovine AHG (Nossel et al, 1962) .
The effect of porcine AHG preparations in vivo and in vitro is not so well defined. Sharp and Bidwell (1957) showed no effect on human platelets in vitro when the porcine preparation was used at 0 5 mg/ml but when the concentration was raised to 5 mg/ml platelet aggregation could be produced. Occasional cases of transient thrombocytopenia have been recorded in human haemophilic patients during therapeutic administration of porcine AHG (Macfarlane et al, 1957; Rizza and Biggs, 1969) .
The present investigation was undertaken in an attempt to identify the platelet aggregating agent and its mechanism of action. ' Present address: Department of Medicine, University of Aberdeen.
Foresterhill, Aberdeen AB9 2ZD. Received for publication 13 September 1971.
Material COLLECTION OF BLOOD
All samples were collected by clean venepuncture from healthy donors using plastic syringes and a mixture made of 9 volumes of blood with 1 volume of 3-8% sodium citrate or 2% ethylenediaminetetracetic acid. All glassware was siliconized using Siliclad (Clay Adams Inc, New Jersey, USA).
PLATELET-RICH PLASMA
This was prepared from citrated whole blood by centrifugation at 600 g for five minutes at room temperature. PORCINE (1962) . The apparatus used in this study consisted of an EEL titrator connected to a galvanometer (EEL type 20, Evans Electroselenium Limited, England). A perspex cuvette was fitted onto a titrator above a magnetic stirrer and in the light path from the photoelectric cell. Plateletrich plasma, 2 ml amounts, was added to the cuvette together with a small stirring rod. When the stirring rod was rotating at a uniform speed, the optical density reading of the plasma sample on the galvanometer scale was adjusted to an arbitrary value of 0 600. The plasma was agitated for 30 seconds to ensure that no change in optical density occurred before the addition of 0-1 ml aliquots of aggregating reagent. Changes in light transmission, at a wavelength of 492 m,u, were recorded at 30-second intervals over a period of 10 minutes from the addition of the AHG. Control samples were handled in an identical fashion except that normal saline replaced the test solution.
PLATELET ADHESIVENESS Platelet adhesiveness was measured by the glass bead column method using the principles described by Hellem (1960) . The glass bead column was made by filling a length of vinyl tubing (NT/13, Portland Plastics, Kent) with 2 5 g Ballotini glass beads (0 57 mm in diameter) to give a column 6 cm in length. The glass beads were held in the column by a filter of fine nylon gauze fitted at each end of the column. Two ml of platelet-rich plasma was incubated for 10 minutes at 37°C with 0-1 ml aliquots of porcine or bovine AHG then drawn into a graduated plastic syringe which was then fitted to an electrically operated mechanical pump. The plasma was pushed through the column of beads at a constant rate. The apparatus used in the study gave a mean contact time between plasma and glass of 30 ± 1 seconds. Platelet counts were performed on the plasma samples before and after passage through the column. The difference between the two counts was expressed as a percentage of the initial platelet count and this value taken as an index of platelet adhesiveness in the sample. This was repeated in seven different plasma samples.
CHANDLER TUBE TECHNIQUE
This was described by Chandler (1958) and modified by Cunningham, McNicol, and Douglas (1965) . The transparent vinyl tubing, 12-3 mm bore, 71 cm in length, was made into loops by means of a nylon adaptor. The loops were washed in cold water and rinsed in 0 9 % sodium chloride. Citrated plateletrich plasma, 5 ml aliquots, was added to the two loops and the volume made up to 15 ml with saline. AHG solution or saline (0.25 ml) was added to the system and the loops were rotated on the turntable of a blood cell suspension mixer (Matburn Limited, London) at 28-5 rpm in a glass-fronted incubator at 37°C. The platelet aggregation was assessed by the length of time taken for the appearance of a 'snowstorm' effect. This was repeated on seven different plasmas.
To determine if the aggregating agent was a protein, an equal volume of 10 % trichloroacetic acid (TCA) was added to the AHG preparations and the resulting precipitate was centrifuged at 2 000 rpm for 10 minutes. A control tube was set up in which an equal volume of saline was added to the AHG preparation. Aliquots (0-1 ml) were then added to platelet-rich plasma in the aggregometer.
Adsorption was performed with calcium phosphate or celite 512, 10 mg/ml of AHG preparation at room temperature. The adsorbent was removed by centrifugation and eluted with 10% sodium chloride. The eluate was dialysed overnight against barbitone-saline buffer. The aggregating activity of the supernatant and the eluate was tested.
EFFECT OF TEMPERATURE
Aliquots of the AHG preparations were kept for 10 minutes in a waterbath at 40°C, 50°C, 60°C, 70°C. Any precipitate which formed was removed by centrifugation at 2000 rpm for 10 minutes. Samples of stock AHG solutions were also kept at -20°C for two years and at room temperature for one week. Of these materials, 0-1 ml amounts were added to 2 ml of platelet-rich plasma in the aggregometer.
EFFECT OF INHIBITORS OF PLATELET AGGREGATION
Adenosine or heparin was incubated with plateletrich plasma at 37°C before the addition of bovine or porcine AHG. The effect of 'aspirin' on AHGinduced platelet aggregation was determined in vitro on the plasma of one subject, the blood having been collected before and two hours after ingestion of four 300 mg tablets.
ASSOCIATION WITH ANTIHAEMOPHILIC GLOBULIN
Bovine and porcine AHG preparations were diluted with saline to give approximately 100% AHG activity as compared with a standard human plasma pool. Aliquots of 2 ml were then incubated for two hours at 37°C with 0-25 ml of plasma from a haemophiliac with a high titre of inhibitor active against human bovine and porcine AHG, or 0-25 ml of haemophilic plasma without inhibitor. Assay of the residual AHG and aggregating agent in the tubes was then performed.
ASSOCIATION OF THE AGGREGATING AGENT WITH FIBRINOGEN
Gel filtration of the AHG preparations was carried out on 2 5 x 40 cm columns of Sephadex G-200 pre-swollen with barbitone-saline. Three ml samples of the bovine and porcine AHG preparations were applied in 10 % sucrose and 3 ml volumes of effluent were collected and measured for AHG activity, aggregating activity, and fibrinogen.
Plasma from the four animal species which produced maximum platelet aggregation was clotted by the addition of 0-025 M CaCl2 and the serum incubated at 37°C for three hours to remove any residual thrombin. Platelet aggregation of the starting plasma was then compared with the incubated serum.
Platelet counts were performed by the method of Dacie (1956) using formol citrate as the diluting fluid.
Antihaemophilic globulin was assayed by the method of Margolis (1958) as modified by Breckenridge and Ratnoff (1962 Figure 3 . Plasma from goat, sheep, pig, cow, and horse produced aggregation of human platelets in vitro. Plasma from a range of primates (chimp, rhesus monkey, black ape, baboon, gibbon, and squirrel monkey) produced very slight, reversible aggregation and plasma from a wide range of animals (dogs, cat, rat, opossum, rabbit, hamster, guinea pig, turkey, pigeon, chicken, paddlefish, and lobster) produced no aggregation. 
EFFECT OF INHIBITORS OF PLATELET AGGREGATION
Aggregation by animal AHG is dependent on the presence of ionic calcium. The addition of ethylene diamine tetracetic acid (EDTA) to the platelet-rich plasma resulted in inhibition of aggregation.
Similarly pre-incubation of platelet-rich plasma with adenosine at a concentration of 50 jig/mil of plasma resulted in inhibition of aggregation. Heparin produced no inhibition of aggregation even in concentrations of 25 units/ml of plasma.
The effect of salicylic acid is shown in Figure 4 . The lower curve shows the biphasic response of platelet aggregation to porcine AHG. The upper curve is the response in the same subject's plateletrich plasma two hours after the ingestion of acetylsalicylic acid. The results indicate progressive destruction of the platelet aggregating factor as the temperature is raised, with complete destruction of aggregating activity when the preparations were kept at 70°C for 10 minutes (Figs. 5a and b) .
The aggregating factor is stable when kept at roonm temperature, for a week and also at -20°C for two years. or calcium phosphate and is therefore not related to the contact or vitamin K-dependent coagulation factors. Aggregation was not inhibited by heparin Ld no effect which inhibits thrombin-induced platelet aggregato the same tion (Clayton and Cross, 1963) .
The pattern of platelet aggregation is biphasic, aggregation starting on addition of AHG without IF THE the delay seen with collagen (Zucker and Borrelli, 1962; Hovig, 1963a and b) . The reaction is dependiity in the ent on calcium ions and is blocked by pre-incubation no differ-of the platelet-rich plasma with adenosine, a competitive inhibitor of endogenous ADP release. The second phase of aggregation can be blocked by prior q ingestion of acetylsalicylic acid which is thought to produce inhibition of release of endogenous n of bovine platelet ADP (Zucker and Peterson, 1968) . hat in both The action of the antihaemophilic globulin in the aggregating AHG preparations is not clear. It is closely related to fibrinogen fractions and is inactivated during the )n of four clotting of plasma. However, when the AHG activity in Figure 6 . of a sample was reduced from 100% of normal to by clotting I % by incubating with a potent AHG inhibitor no iggregating change in platelet aggregation occurred. rely. Mason, and Brinkhous (1960) , Brinkhous, Read, and Mason (1965) , and Mason and Read (1967) who described an activity present in the fibri-8 9 10 nogen fraction of various animal species which they called thrombocyte agglutinating activity (TAg).
m various
The mechanism by which animal fibrinogens ratelets.
aggregate human platelets is unknown but may reflect species differences in the fibrinogen molecule (Doolittle and Blomback, 1964) . Bovine fibrinogen has been used as a platelet aggregating agent by Caen, Castaldi, Leclerc, Inceman, Larrieu, Probst, tions cause and Bernard (1966a) and by Caen, Vainer, and Gautier nd in vitro. (1966b) in patients with thrombasthenia whose asma from platelets were not aggregated by ADP, adrenaline, )und in the noradrenaline, 5-hydroxytryptamine, thrombin, iggregating purified collagen, crude connective tissue, or human ates but is fibrinogen. However, bovine fibrinogen at a concenall fish and tration of 1*5 mg/ml produced aggregation in five of the six cases tested. They also showed that the d by 10% aggregating activity could be destroyed on incubagroup.bmj.com on April 5, 2017 -Published by http://jcp.bmj.com/ Downloaded from tion with plasmin and the reaction does not consume complement. Falcao, Probst, Gautier, Vainer, Michel, and Caen (1967) , using the electron microscope, showed that the intercellular cement in the external membranes was unaltered in platelets aggregated by bovine fibrinogen.
Infusion of animal AHG preparations in haemophilic patients gives rise to thrombocytopenia which is transient and is related to the dose given. Thrombocytopenia is probably due to trapping of the large platelet aggregates in the capillaries, a phenomenon which is similar to the retention of platelet aggregates in the Hellem glass bead columns. Bleeding as a result of the low platelet count has been occasionally documented (Macfarlane and Biggs, 1959; Hall, Handley, and Webster, 1962; Rizza and Biggs, 1969) , despite a normal or high level of AHG. In one of our patients (case 3) there was no rise in the plasma level of AHG due to inactivation by inhibitor but there was evidence of increased gastrointestinal blood loss with a rise in blood transfusion requirements and a fall in haemoglobin which corresponded in time to the thrombocytopenic episode.
All three of our patients experienced pain along the line of the vein through which the AHG solution was administered and also suffered thrombosis in the veins at the infusion site. This thrombogenic effect has been recorded previously (Biggs, 1960) and may be due to adherence of platelet aggregates to the endothelium of the vein with production of platelet thrombi as suggested by Berman and Fulton (1961) and Mustard, Murphy, Rowsell, and Downie (1962) . Such platelet thrombi may stimulate formation of fibrin with resultant occlusion of the vessel.
Examination of a blood film in one of our patients during infusion of porcine AHG showed multiple platelet aggregates consisting of 30 to 50 platelets, measuring 100-200 ,u (Born and Cross, 1963) , swine Murphy, Mustard, Rowsell, and Downie, 1964) , and in rabbits (Regoli and Clark, 1963) . In experimental animals, platelet aggregates induced by ADP can be seen histologically blocking capillaries in the lung (Nordoy and Chandler, 1967) where they may produce irreversible tissue changes even though the platelet thrombus itself is transient. Mustard et al (1964) produced myocardial infarction in swine by infusion of ADP, and in the rat infusion of ADP may result in respiratory arrest with platelet thrombi in the pulmonary capillaries, a reaction that can be produced under experimental conditions by the injection of other embolizing particles (De Takats, Beck, and Fenn, 1939) . In the rabbit, if platelet aggregates are formed within the renal circulation, focal acute glomerulonephritis is produced with areas of cortical necrosis (Glynn, J0rgensen, and Buchanan, 1966) . In these experiments fibrin thrombi were found in the renal arteries and glomerular capillaries 24 hours after ADP infusion. This finding was interpreted by the authors as indicating that the fibrin thrombi were secondary to the platelet aggregates occluding blood flow.
In the original toxicity studies by Sharp and Bidwell (1957) injection of AHG preparations into rabbits produced no histological changes of note. This was probably because rabbit platelets are not aggregated by bovine or porcine AHG preparations. This is in keeping with the finding of LeRoy et al (1960) that there is marked interspecies differences to a range of aggregating agents.
Despite wide usage of these preparations there has been no clinical evidence of myocardial or pulmonary complications in patients receiving bovine or porcine AHG. In one case (Wardle, 1967) , proteinuria developed during a course of bovine AHG which also produced thrombocytopenia. Proteinuria and biochemical evidence of renal damage was present in this patient three months later.
With the increased availability of human concentrates of AHG the need for animal AHG preparations will diminish, but they still will be of value in patients with inhibitors, perhaps in combination with exchange transfusion (Roberts, Scales, Madison, Webster, and Penick, 1965) . In particular modern fractionation methods may permit large scale separation of the potent AHG fraction from the platelet-aggregating fibrinogen fraction.
